Creative Medical Technology Holdings, Inc. announced that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration.
Creative Medical Technology Holdings, Inc.
Equities
CELZ
US22529Y4089
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.396 USD | +2.24% | +0.03% | -4.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.63% | 5.83M | |
+3.34% | 108B | |
+10.81% | 104B | |
+1.28% | 22.33B | |
-12.07% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.85% | 17.64B | |
+4.88% | 14.05B | |
+34.64% | 12.51B |
- Stock Market
- Equities
- CELZ Stock
- News Creative Medical Technology Holdings, Inc.
- Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line